What can we learn from Mirati’s adagrasib in lung and other cancers?
What’s the elephant in the KRASi room?
It’s time to look at the latest update on KRAS mutation specific agents in clinical development as we turn the spotlight from the Amgen sotorasib data at ESMO to Mirati’s G12C selective agent, MRTX849, now known as adagrasib.
At the Targets meeting last year in Boston, Dr Pasi Jänne presented the initial findings from phase 1/1b the lung cancer cohort. This time around we get to hear him provide an update on the combined phase 1/1b plus phase 2 results, plus there’s an additional presentation from Dr Melissa Johnson on the non-lung cancer cohort i.e. GI and other cancers.
Ahead of the presentation this morning (US east coast time), BSB caught up with Dr Jänne for his perspectives on the progress made and where things are headed in the near-term. He offers a thoughtful and candid approach to tackling a hard to treat cancer subset with targeted therapy.
To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the EORTC-NCI-AACR Triple meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
